| Status | Awaiting development |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | Topic in appraisal. |
| Process | STA Standard |
| ID number | 6426 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 01 May 2024 | Awaiting development. NICE will be undertaking an managed access review of Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. This was originally TA963 The appraisal is expected to start during early-July 2024 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during late-July 2024. The deadline for submissions is expected in approximately late-September 2024. |
| 01 May 2024 | NICE will be undertaking an managed access review of Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. This was originally TA963 The appraisal is expected to start during early-July 2024 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during late-July 2024. The deadline for submissions is expected in approximately late-September 2024. |
| 11 April 2024 | In progress |
For further information on how we select topics for development, please see our page about topic selection